3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
6
Colorectal Neoplasms
4
Carcinoma, Transitional Cell
4
Non-Muscle Invasive Bladder Neoplasms
3
Neoplasm Metastasis
3
Colonic Neoplasms
3
Anus Neoplasms
3
Sarcoma
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Carcinoma in Situ
2
Virus Diseases
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urinary Bladder Diseases
1
Neoplasms by Site
1
Neoplasm Recurrence, Local
1
Nasopharyngeal Carcinoma
1
Mycobacterium Infections
1
Head and Neck Neoplasms
1
Epstein-Barr Virus Infections
1
Disease
1
Dermatitis
1
Carcinoma, Hepatocellular
1
Adenoviridae Infections
1
Interventions
valrubicin
1
temsirolimus
1
pembrolizumab
1
palbociclib
1
niraparib
1
enfortumab vedotin
1
cabozantinib
1
atezolizumab
1
Zoledronic Acid
1
Valproic Acid
1
VMBP protocol
1
Trastuzumab
1
Sunitinib
1
Standard of Care
1
Sirolimus
1
Prednisone
1
Nivolumab
1
Mitomycin
1
Immunoglobulin G
1
Gemcitabine
1
Etoposide
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Cisplatin
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urologic Neoplasms
×
Mitomycin
×
Clear all
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts